Patents by Inventor Sushma Kommareddy

Sushma Kommareddy has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Zika vaccines and immunogenic compositions, and methods of using the same
    Patent number: 11975062
    Abstract: The present disclosure relates to Zika virus vaccines and immunogenic compositions having one or more antigens from a Zika virus (e.g., a Zika virus clonal isolate, a non-human cell adapted Zika virus, etc.), and methods of treatments and uses thereof.
    Type: Grant
    Filed: November 30, 2018
    Date of Patent: May 7, 2024
    Assignee: Takeda Vaccines, Inc.
    Inventors: Jill A. Livengood, Hansi Dean, Htay Htay Han, Raman Rao, Jackie Marks, Gary Dubin, Laurence De Moerlooze, Hetal Patel, Asae Shintani, Holli Giebler, James Gifford, Mark Lyons, Sushma Kommareddy, Tatsuki Satou
  • Method for inactivating zika virus and for determining the completeness of inactivation
    Patent number: 11964008
    Abstract: The present disclosure relates to methods for inactivating a Zika virus which can be used in vaccines and immunogenic compositions. The present disclosure also relates to a method for determining the completeness of inactivation of an arbovirus preparation.
    Type: Grant
    Filed: September 13, 2022
    Date of Patent: April 23, 2024
    Assignee: Takeda Vaccines, Inc.
    Inventors: Jill A. Livengood, Holli Giebler, Hansi Dean, Tatsuki Satou, Raman Rao, Jackie Marks, Mark Lyons, Asae Shintani, James Gifford, Sushma Kommareddy
  • METHOD FOR INACTIVATING ZIKA VIRUS AND RELATED METHODS
    Publication number: 20240024454
    Abstract: The present disclosure relates to methods for inactivating a Zika virus which can be used in vaccines and immunogenic compositions. The present disclosure also relates to a method for determining the completeness of inactivation of an arbovirus preparation and to a method for determining the residual formaldehyde content in a pharmaceutical composition comprising an inactivated virus.
    Type: Application
    Filed: June 22, 2023
    Publication date: January 25, 2024
    Inventors: Jill A. LIVENGOOD, Holli Giebler, Hansi Dean, Tatsuki Satou, Raman Rao, Jackie Marks, Mark Lyons, Asae Shintani, James Gifford, Nao Ogasawara, Masafumi Misaki, Satoshi Adachi, Sushma Kommareddy
  • ZIKA VACCINES AND IMMUNOGENIC COMPOSITIONS, AND METHODS OF USING THE SAME
    Publication number: 20230414743
    Abstract: The present disclosure relates to Zika virus vaccines and immunogenic compositions having one or more antigens from a Zika virus (e.g., a Zika virus clonal isolate, a non-human cell adapted Zika virus, etc.), and methods of treatments and uses thereof.
    Type: Application
    Filed: June 16, 2023
    Publication date: December 28, 2023
    Inventors: Jill A. LIVENGOOD, Hansi DEAN, Htay Htay HAN, Raman RAO, Jackie MARKS, Gary DUBIN, Laurence DE MOERLOOZE, Hetal PATEL, Sushma KOMMAREDDY
  • ZIKA VACCINES AND IMMUNOGENIC COMPOSITIONS, AND METHODS OF USING THE SAME
    Publication number: 20230398199
    Abstract: The present disclosure relates to Zika virus vaccines and immunogenic compositions having one or more antigens from a Zika virus (e.g., a Zika virus clonal isolate, a non-human cell adapted Zika virus, etc.
    Type: Application
    Filed: November 30, 2018
    Publication date: December 14, 2023
    Inventors: Jill A. LIVENGOOD, Hansi DEAN, Htay Htay HAN, Raman RAO, Jackie MARKS, Gary DUBIN, Laurence DE MOERLOOZE, Hetal PATEL, Asae SHINTANI, Holli GIEBLER, James GIFFORD, Mark LYONS, Sushma KOMMAREDDY, Tatsuki SATOU
  • Zika vaccines and immunogenic compositions, and methods of using the same
    Patent number: 11730802
    Abstract: The present disclosure relates to Zika virus vaccines and immunogenic compositions having one or more antigens from a Zika virus (e.g., a Zika virus clonal isolate, a non-human cell adapted Zika virus, etc.), and methods of treatments and uses thereof.
    Type: Grant
    Filed: November 5, 2018
    Date of Patent: August 22, 2023
    Assignee: Takeda Vaccines, Inc.
    Inventors: Jill A Livengood, Hansi Dean, Htay Htay Han, Raman Rao, Jackie Marks, Gary Dubin, Laurence De Moerlooze, Hetal Patel, Sushma Kommareddy
  • METHOD FOR INACTIVATING ZIKA VIRUS AND FOR DETERMINING THE COMPLETENESS OF INACTIVATION
    Publication number: 20230145065
    Abstract: The present disclosure relates to methods for inactivating a Zika virus which can be used in vaccines and immunogenic compositions. The present disclosure also relates to a method for determining the completeness of inactivation of an arbovirus preparation.
    Type: Application
    Filed: September 13, 2022
    Publication date: May 11, 2023
    Applicant: TAKEDA VACCINES, INC.
    Inventors: Jill A. LIVENGOOD, Holli Giebler, Hansi Dean, Tatsuki Satou, Raman Rao, Jackie Marks, Mark Lyons, Asae Shintani, James Gifford, Sushma Kommareddy
  • INACTIVATED VIRUS COMPOSITIONS AND ZIKA VACCINE FORMULATIONS
    Publication number: 20220211836
    Abstract: The present invention relates to a liquid inactivated virus composition comprising: an inactivated whole Zika virus, at least one pharmaceutically acceptable buffer with a concentration of at least about 6.5 mM, and optionally a polyol, wherein said at least one pharmaceutically acceptable buffer does not comprise phosphate ions and vaccines derived therefrom.
    Type: Application
    Filed: April 8, 2020
    Publication date: July 7, 2022
    Applicant: Takeda Vaccines, Inc.
    Inventors: Michael JOHNSON, Sushma KOMMAREDDY
  • ZIKA VACCINES AND IMMUNOGENIC COMPOSITIONS, AND METHODS OF USING THE SAME
    Publication number: 20210177958
    Abstract: The present disclosure relates to Zika virus vaccines and immunogenic compositions having one or more antigens from a Zika virus (e.g., a Zika virus clonal isolate, a non-human cell adapted Zika virus, etc.), and methods of treatments and uses thereof.
    Type: Application
    Filed: November 5, 2018
    Publication date: June 17, 2021
    Inventors: Jill A LIVENGOOD, Hansi DEAN, Htay Htay HAN, Raman RAO, Jackie MARKS, Gary DUBIN, Laurence DE MOERLOOZE, Hetal PATEL, Sushma KOMMAREDDY
  • Benzonaphthyridine-containing vaccines
    Patent number: 9517263
    Abstract: The invention provides, inter alia, immunogenic compositions that comprise (a) a first antigen, (b) polymeric particles and (c) a benzonaphthyridine compound, which compositions elicits an immune response when administered to a vertebrate subject. The invention also provides, inter alia, methods of producing immunogenic compositions and methods for using immunogenic compositions (e.g., for treatment), among other benefits.
    Type: Grant
    Filed: June 10, 2010
    Date of Patent: December 13, 2016
    Assignee: GlaxoSmithKline Biologicals SA
    Inventors: Derek O'Hagan, Manmohan Singh, Siddhartha Jain, Sushma Kommareddy
  • CONCENTRATION OF VACCINE ANTIGENS WITH LYOPHILIZATION
    Publication number: 20130243841
    Abstract: A process for preparing a lyophilised vaccine antigen, comprising steps of (i) increasing the concentration of an antigen in a liquid composition including that antigen using centrifugal filtration and/or ultrafiltration, to provide a concentrated antigen, and (ii) lyophilising the concentrated antigen, to provide the lyophilised vaccine antigen. The lyophilised material can be reconstituted and used for vaccine formulation. The process is particularly useful with influenza vaccine antigens.
    Type: Application
    Filed: June 1, 2011
    Publication date: September 19, 2013
    Applicant: Novartis AG
    Inventors: Sushma Kommareddy, Derek O'Hagan, Manmohan Singh, Amanda Scampini Bonificio, Barbara Baudner
  • CONCENTRATION OF VACCINE ANTIGENS WITHOUT LYOPHILIZATION
    Publication number: 20130224245
    Abstract: An antigen concentration procedure does not involve lyophilisation of a bulk antigen before its final formulation and/or delivery. Thus a process for preparing a vaccine comprises steps of (i) increasing the concentration of an antigen in a liquid composition including that antigen, to provide a concentrated antigen, and (ii) formulating a vaccine from the concentrated antigen. The concentrated antigen is not lyophilised between or during steps (i) and (ii). The invention is particularly useful for preparing solid vaccine forms.
    Type: Application
    Filed: June 1, 2011
    Publication date: August 29, 2013
    Applicant: Novartis AG
    Inventors: Sushma Kommareddy, Derek O'Hagan, Manmohan Singh, Amanda Bonoficio, Barbara Baudner
  • BENZONAPHTHYRIDINE-CONTAINING VACCINES
    Publication number: 20120263753
    Abstract: The invention provides, inter alia, immunogenic compositions that comprise (a) a first antigen, (b) polymeric particles and (c) a benzonaphthyridine compound, which compositions elicits an immune response when administered to a vertebrate subject. The invention also provides, inter alia, methods of producing immunogenic compositions and methods for using immunogenic compositions (e.g., for treatment), among other benefits.
    Type: Application
    Filed: June 10, 2010
    Publication date: October 18, 2012
    Applicant: NOVARTIS AG
    Inventors: Derek O'Hagan, Manmohan Singh, Siddhartha Jain, Sushma Kommareddy